Login to Your Account


No Johnson magic?
Analysts pelted Abbvie Inc. with questions after its disclosure of the surprise $21 billion deal to take over Pharmacyclics Inc., but most agreed that the asset Imbruvica (ibrutinib) is well worth having aboard. more »

Our Habitat for All Things Science
Blocking antioxidant pathways stops tumors in their tracks

Antioxidants seem to be on a Bill Cosby-like downward spiral from wholesomeness to villainy.

The newest accusations can be found in the Feb. 9, 2015, issue of Cancer Cell, where scientists reported that antioxidants drove both the initiation and the progression of tumors, and that blocking antioxidant pathways could destroy tumor cells.

Because they scavenge free radicals, which induce DNA damage as well as other damage in cells, antioxidants were once thought to protect against cancer.

That idea, however, has not held up to scientific scrutiny.

READ MORE »

Opinion


Partners in Focus